State of New Jersey Common Pension Fund D Sells 35,987 Shares of Catalent, Inc. (NYSE:CTLT)

State of New Jersey Common Pension Fund D lessened its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 34.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,078 shares of the company's stock after selling 35,987 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Catalent were worth $3,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company's stock worth $1,151,872,000 after acquiring an additional 218,682 shares in the last quarter. Capital World Investors grew its position in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company's stock valued at $857,264,000 after acquiring an additional 1,098,474 shares during the last quarter. Cadian Capital Management LP raised its position in Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company's stock worth $272,473,000 after purchasing an additional 759,600 shares during the period. Capital International Investors increased its holdings in shares of Catalent by 1.2% in the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company's stock worth $134,541,000 after buying an additional 34,856 shares during the period. Finally, Norges Bank bought a new stake in Catalent in the fourth quarter valued at approximately $116,021,000.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. StockNews.com started coverage on shares of Catalent in a research note on Wednesday. They set a "sell" rating on the stock. Barclays increased their target price on Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a research note on Friday, June 28th. Finally, William Blair reissued a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $58.08.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of the company's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Ricky Hopson sold 662 shares of the business's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company's stock, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of the company's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company's stock, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders have sold 13,409 shares of company stock worth $782,923 in the last quarter. Company insiders own 0.31% of the company's stock.

Catalent Stock Performance

Catalent stock traded down $0.05 during mid-day trading on Wednesday, reaching $60.30. 2,431,479 shares of the stock traded hands, compared to its average volume of 2,105,335. The business's 50-day moving average is $59.39 and its 200-day moving average is $57.17. The stock has a market capitalization of $10.91 billion, a PE ratio of -9.89, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.